Oseltamivir therapy in two low birth-weight premature infants born to women with H1N1 influenza.
The influenza A (H1N1) virus may cause severe illness in humans, especially children less than two years of age. The neuraminidase enzyme inhibitor, oseltamivir, is a potent medication for the management of patients with this infection. Minimal information exists regarding the immediate and long term effects of oseltamivir therapy in low birth weight premature infants born to mothers with this viral illness. This is a review of two premature male infants born to mothers with influenza A (H1N1), their presentation, clinical course, administration of oseltamivir, medical management and long term follow up through the first 18 months of life.
University of Puerto Rico School of Medicine, Department of Pediatrics, Neonatology Section, San Juan, Puerto Rico. alessandro.acosta@upr.edu
Alessandro M
AM
Acosta
Inés
I
García
García
G
Lourdes
ZiIkia
Z
Rivera
Juan
J
Rivera
Marta
M
Valcárcel
D000998:Antiviral Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007223:Infant; D007230:Infant, Low Birth Weight; D007231:Infant, Newborn; D007232:Infant, Newborn, Diseases / Q000188:drug therapy* / Q000821:virology*; D007234:Infant, Premature; D007235:Infant, Premature, Diseases / Q000188:drug therapy* / Q000821:virology*; D053118:Influenza A Virus, H1N1 Subtype; D007251:Influenza, Human / Q000188:drug therapy*; D008297:Male; D053139:Oseltamivir / Q000627:therapeutic use*
D000998:Antiviral Agents; D053139:Oseltamivir